Janet L. Oblinger, Ph.D.
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Area:
pathobiology of brain cancerGoogle:
"Janet Oblinger"Mean distance: 20037.4
Parents
Sign in to add mentor| Allan James Yates | grad student | 2002 | Ohio State | |
| (Cell-context-dependent modulation of receptor tyrosine kinases by ganglioside GM1.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Oblinger JL, Wang J, Wetherell GD, et al. (2024) Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas. Scientific Reports. 14: 19349 |
| Oblinger J, Wang J, Wetherell G, et al. (2024) Anti-tumor Effects of the eIF4A Inhibitor Didesmethylrocaglamide and Its Derivatives in Human and Canine Osteosarcomas. Research Square |
| Chang LS, Oblinger JL, Burns SS, et al. (2019) Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas. Molecular Cancer Therapeutics |
| Angus SP, Oblinger JL, Stuhlmiller TJ, et al. (2018) EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology |
| Oblinger JL, Burns SS, Huang J, et al. (2017) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology |
| Oblinger JL, Burns SS, Akhmametyeva EM, et al. (2016) Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology |
| Burns SS, Akhmametyeva EM, Oblinger JL, et al. (2013) Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Research. 73: 792-803 |
| Bush ML, Burns SS, Oblinger J, et al. (2012) Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 33: 244-57 |
| Jacob A, Oblinger J, Bush ML, et al. (2012) Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89 |
| Bush ML, Oblinger J, Brendel V, et al. (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99 |